147 related articles for article (PubMed ID: 10037195)
1. Increased sensitivity of hydroxyurea-resistant leukemic cells to gemcitabine.
Wong SJ; Myette MS; Wereley JP; Chitambar CR
Clin Cancer Res; 1999 Feb; 5(2):439-43. PubMed ID: 10037195
[TBL] [Abstract][Full Text] [Related]
2. The role of DNA synthesis inhibition in the cytotoxicity of 2',2'-difluoro-2'-deoxycytidine.
Ostruszka LJ; Shewach DS
Cancer Chemother Pharmacol; 2003 Oct; 52(4):325-32. PubMed ID: 12811514
[TBL] [Abstract][Full Text] [Related]
3. Interaction of gallium nitrate with other inhibitors of ribonucleotide reductase: effects on the proliferation of human leukemic cells.
Myette MS; Elford HL; Chitambar CR
Cancer Lett; 1998 Jul; 129(2):199-204. PubMed ID: 9719462
[TBL] [Abstract][Full Text] [Related]
4. Mechanism for induction of hydroxyurea resistance and loss of latent EBV genome in hydroxyurea-treated Burkitt's lymphoma cell line Raji.
Jiang R; Zhang JL; Satoh Y; Sairenji T
J Med Virol; 2004 Aug; 73(4):589-95. PubMed ID: 15221904
[TBL] [Abstract][Full Text] [Related]
5. Ribonucleotide reductase is an effective target to overcome gemcitabine resistance in gemcitabine-resistant pancreatic cancer cells with dual resistant factors.
Minami K; Shinsato Y; Yamamoto M; Takahashi H; Zhang S; Nishizawa Y; Tabata S; Ikeda R; Kawahara K; Tsujikawa K; Chijiiwa K; Yamada K; Akiyama S; Pérez-Torras S; Pastor-Anglada M; Furukawa T; Yasuo T
J Pharmacol Sci; 2015 Mar; 127(3):319-25. PubMed ID: 25837929
[TBL] [Abstract][Full Text] [Related]
6. Effects of 2',2'-difluorodeoxycytidine (Gemcitabine) on wild type and variant mouse leukemia L1210 cells.
Cory AH; Hertel LW; Kroin JS; Cory JG
Oncol Res; 1993; 5(2):59-63. PubMed ID: 8364254
[TBL] [Abstract][Full Text] [Related]
7. Increased expression of the large subunit of ribonucleotide reductase is involved in resistance to gemcitabine in human mammary adenocarcinoma cells.
Jordheim LP; Guittet O; Lepoivre M; Galmarini CM; Dumontet C
Mol Cancer Ther; 2005 Aug; 4(8):1268-76. PubMed ID: 16093443
[TBL] [Abstract][Full Text] [Related]
8. Difluorodeoxyguanosine: cytotoxicity, metabolism, and actions on DNA synthesis in human leukemia cells.
Gandhi V; Mineishi S; Huang P; Yang Y; Chubb S; Chapman AJ; Nowak BJ; Hertel LW; Plunkett W
Semin Oncol; 1995 Aug; 22(4 Suppl 11):61-7. PubMed ID: 7481847
[TBL] [Abstract][Full Text] [Related]
9. Combined use of subclinical hydroxyurea and CHK1 inhibitor effectively controls melanoma and lung cancer progression, with reduced normal tissue toxicity compared to gemcitabine.
Oo ZY; Proctor M; Stevenson AJ; Nazareth D; Fernando M; Daignault SM; Lanagan C; Walpole S; Bonazzi V; Škalamera D; Snell C; Haass NK; Larsen JE; Gabrielli B
Mol Oncol; 2019 Jul; 13(7):1503-1518. PubMed ID: 31044505
[TBL] [Abstract][Full Text] [Related]
10. Hydroxyurea decreases gemcitabine resistance in pancreatic carcinoma cells with highly expressed ribonucleotide reductase.
Funamizu N; Kamata Y; Misawa T; Uwagawa T; Lacy CR; Yanaga K; Manome Y
Pancreas; 2012 Jan; 41(1):107-13. PubMed ID: 21926937
[TBL] [Abstract][Full Text] [Related]
11. Effect of hydroxyurea on cellular iron metabolism in human leukemic CCRF-CEM cells: changes in iron uptake and the regulation of transferrin receptor and ferritin gene expression following inhibition of DNA synthesis.
Chitambar CR; Wereley JP
Cancer Res; 1995 Oct; 55(19):4361-6. PubMed ID: 7671248
[TBL] [Abstract][Full Text] [Related]
12. Differential effect of collaterally sensitive antimetabolites on P388 murine leukemia sensitive and resistant to adriamycin in vitro.
Satyamoorthy K; Deshpande SS; Chitnis MP
Neoplasma; 1989; 36(6):673-83. PubMed ID: 2515459
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines.
Gourdeau H; Clarke ML; Ouellet F; Mowles D; Selner M; Richard A; Lee N; Mackey JR; Young JD; Jolivet J; Lafrenière RG; Cass CE
Cancer Res; 2001 Oct; 61(19):7217-24. PubMed ID: 11585758
[TBL] [Abstract][Full Text] [Related]
14. Cross-resistance patterns in hydroxyurea-resistant leukemia L1210 cells.
Carter GL; Cory JG
Cancer Res; 1988 Oct; 48(20):5796-9. PubMed ID: 2844392
[TBL] [Abstract][Full Text] [Related]
15. Comparison of antineoplastic activity of 2',2'-difluorodeoxycytidine and cytosine arabinoside against human myeloid and lymphoid leukemic cells.
Bouffard DY; Momparler LF; Momparler RL
Anticancer Drugs; 1991 Feb; 2(1):49-55. PubMed ID: 1958852
[TBL] [Abstract][Full Text] [Related]
16. A small-molecule blocking ribonucleotide reductase holoenzyme formation inhibits cancer cell growth and overcomes drug resistance.
Zhou B; Su L; Hu S; Hu W; Yip ML; Wu J; Gaur S; Smith DL; Yuan YC; Synold TW; Horne D; Yen Y
Cancer Res; 2013 Nov; 73(21):6484-93. PubMed ID: 24072748
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of ribonucleotide reductase by a new class of isoindole derivatives: drug synergism with cytarabine (Ara-C) and induction of cellular apoptosis.
Nandy P; Lien EJ; Avramis VI
Anticancer Res; 1999; 19(3A):1625-33. PubMed ID: 10470093
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine: metabolism, mechanisms of action, and self-potentiation.
Plunkett W; Huang P; Xu YZ; Heinemann V; Grunewald R; Gandhi V
Semin Oncol; 1995 Aug; 22(4 Suppl 11):3-10. PubMed ID: 7481842
[TBL] [Abstract][Full Text] [Related]
19. Induction of resistance to 2',2'-difluorodeoxycytidine in the human ovarian cancer cell line A2780.
Ruiz van Haperen VW; Veerman G; Eriksson S; Stegmann AP; Peters GJ
Semin Oncol; 1995 Aug; 22(4 Suppl 11):35-41. PubMed ID: 7481843
[TBL] [Abstract][Full Text] [Related]
20. Time and sequence dependence of hydroxyurea in combination with gemcitabine in human KB cells.
Zhou B; Mi S; Mo X; Shih J; Tsai J; Hu E; Hsu M; Kay K; Yen Y
Anticancer Res; 2002; 22(3):1369-77. PubMed ID: 12168813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
